Sutro Biopharma (STRO) Change in Receivables (2017 - 2025)

Sutro Biopharma has disclosed Change in Receivables across 9 years of filings, most recently posting $55000.0 for Q4 2025.

• Change in Receivables for Q4 2025 came in at $55000.0, down 97.2% year-over-year; the trailing twelve-month figure through Dec 2025 was -$4.6 million (up 83.11% YoY), and the FY2025 annual result was -$4.6 million, up 83.11% from the prior year.
• Change in Receivables came in at $55000.0 for Q4 2025 at Sutro Biopharma, up from -$4.1 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $86.0 million in Q2 2022 to a low of -$86.4 million in Q3 2022.
• The 5-year median for Change in Receivables is $125000.0 (2021), against an average of -$79550.0.
• Across the five-year window, Change in Receivables soared 4348.27% in 2022 and sank 19425.4% in 2024, its largest moves.
• Sutro Biopharma's Change in Receivables stood at $124000.0 in 2021, then slumped by 3429.03% to -$4.1 million in 2022, then surged by 571.2% to $19.5 million in 2023, then slumped by 89.92% to $2.0 million in 2024, then plunged by 97.2% to $55000.0 in 2025.
• The last three Change in Receivables figures came in at $55000.0 (Q4 2025), -$4.1 million (Q3 2025), and -$5.6 million (Q2 2025), per Business Quant data.